Artificial intelligence for diagnosing exudative age‐related macular degeneration

Background Age‐related macular degeneration (AMD) is a retinal disorder characterized by central retinal (macular) damage. Approximately 10% to 20% of non‐exudative AMD cases progress to the exudative form, which may result in rapid deterioration of central vision. Individuals with exudative AMD (eA...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cochrane database of systematic reviews 2024-10, Vol.2024 (10), p.CD015522
Hauptverfasser: Greenberg, Paul B, Kang, Chaerim, Lo, Jui-En, Zhang, Helen, Ng, Sueko M, Lin, John C, Scott, Ingrid U, Kalpathy-Cramer, Jayashree, Liu, Su-Hsun (Alison)
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Age‐related macular degeneration (AMD) is a retinal disorder characterized by central retinal (macular) damage. Approximately 10% to 20% of non‐exudative AMD cases progress to the exudative form, which may result in rapid deterioration of central vision. Individuals with exudative AMD (eAMD) need prompt consultation with retinal specialists to minimize the risk and extent of vision loss. Traditional methods of diagnosing ophthalmic disease rely on clinical evaluation and multiple imaging techniques, which can be resource‐consuming. Tests leveraging artificial intelligence (AI) hold the promise of automatically identifying and categorizing pathological features, enabling the timely diagnosis and treatment of eAMD. Objectives To determine the diagnostic accuracy of artificial intelligence (AI) as a triaging tool for exudative age‐related macular degeneration (eAMD). Search methods We searched CENTRAL, MEDLINE, Embase, three clinical trials registries, and Data Archiving and Networked Services (DANS) for gray literature. We did not restrict searches by language or publication date. The date of the last search was April 2024. Selection criteria Included studies compared the test performance of algorithms with that of human readers to detect eAMD on retinal images collected from people with AMD who were evaluated at eye clinics in community or academic medical centers, and who were not receiving treatment for eAMD when the images were taken. We included algorithms that were either internally or externally validated or both. Data collection and analysis Pairs of review authors independently extracted data and assessed study quality using the Quality Assessment of Diagnostic Accuracy Studies‐2 (QUADAS‐2) tool with revised signaling questions. For studies that reported more than one set of performance results, we extracted only one set of diagnostic accuracy data per study based on the last development stage or the optimal algorithm as indicated by the study authors. For two‐class algorithms, we collected data from the 2x2 table whenever feasible. For multi‐class algorithms, we first consolidated data from all classes other than eAMD before constructing the corresponding 2x2 tables. Assuming a common positivity threshold applied by the included studies, we chose random‐effects, bivariate logistic models to estimate summary sensitivity and specificity as the primary performance metrics. Main results We identified 36 eligible studies that reported 40 sets
ISSN:1465-1858
1469-493X
1465-1858
1469-493X
DOI:10.1002/14651858.CD015522.pub2